Edition:
United States

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

35.47USD
3:59pm EST
Change (% chg)

$-1.08 (-2.95%)
Prev Close
$36.55
Open
$36.76
Day's High
$36.76
Day's Low
$34.72
Volume
215,294
Avg. Vol
285,019
52-wk High
$38.13
52-wk Low
$13.51

Chart for

About

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $832.57
Shares Outstanding(Mil.): 22.78
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

Nov 02 2017

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​ Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 01 2017

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​ Source text : (http://bit.ly/2lnW6oI) Further company coverage:

Oct 27 2017

BRIEF-Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI

* FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage:

Oct 11 2017

BRIEF-Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica

* Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing

Oct 06 2017

BRIEF-Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​

* Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing ‍​ Source text: [http://bit.ly/2xSxczx] Further company coverage:

Sep 07 2017

BRIEF-Adamas announces topline phase 1b data of ADS-4101 for the treatment of partial onset seizures in epilepsy

* Adamas announces topline phase 1b data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy

Sep 07 2017

Adamas Pharma secures approval for Parkinson's dyskinesia drug

The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading.

Aug 24 2017

Adamas Pharma secures approval for Parkinson's dyskinesia drug

Aug 24 The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading.

Aug 24 2017

Earnings vs. Estimates